Gilead Sciences's Options Frenzy: What You Need to Know
Gilead Sciences's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GILD usually suggests something big is about to happen.
深口袋的投資者對吉利德科學 (納斯達克:GILD) 採取了看淡的態度，市場參與者不應忽視。我們在 Benzinga 跟蹤的公開期權記錄中發現了這一重大動態。這些投資者的身份尚不明確，但 GILD 的這種重大變動通常意味着有重大事情即將發生。
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Gilead Sciences. This level of activity is out of the ordinary.
我們從今天的觀察中得知這一信息，當Benzinga的選項掃描器突出顯示吉利德科學的15項非凡的期權交易活動時。這種活動水平是不同尋常的。
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 60% bearish. Among these notable options, 4 are puts, totaling $214,328, and 11 are calls, amounting to $708,487.
這些重量級投資者的總體心情是分裂的，33% 傾向於看漲，而 60% 看淡。在這些值得關注的期權中，有 4 筆看跌期權，總金額爲 $214,328，11 筆看漲期權，總金額爲 $708,487。
What's The Price Target?
價格目標是什麼？
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $74.0 for Gilead Sciences, spanning the last three months.
通過對成交量和未平倉合約進行評估，顯然主要的市場推手正在關注 Gilead Sciences 60.0 到 74.0 美元之間的價格區間，跨越過去三個月。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
In terms of liquidity and interest, the mean open interest for Gilead Sciences options trades today is 1121.55 with a total volume of 994.00.
就流動性和關注度而言，吉利德科學期權交易今天的平均未平倉合約爲 1121.55，總成交量爲 994.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Gilead Sciences's big money trades within a strike price range of $60.0 to $74.0 over the last 30 days.
在以下的圖表中，我們能夠跟蹤過去 30 天內 Gilead Sciences 大手交易的看跌和看漲期權的成交量和未平倉合約的發展，其行使價格在 60.0 到 74.0 美元的範圍內。
Gilead Sciences Call and Put Volume: 30-Day Overview
Gilead Sciences 看漲和看跌期權成交量：30 天概覽
Significant Options Trades Detected:
檢測到重大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | SWEEP | BULLISH | 01/17/25 | $7.0 | $6.85 | $7.0 | $70.00 | $157.5K | 2.8K | 111 |
| GILD | CALL | SWEEP | BEARISH | 07/19/24 | $11.85 | $11.6 | $11.69 | $60.00 | $116.1K | 469 | 100 |
| GILD | PUT | SWEEP | BULLISH | 09/20/24 | $3.9 | $3.75 | $3.75 | $72.50 | $96.7K | 78 | 2 |
| GILD | CALL | SWEEP | BEARISH | 08/16/24 | $9.85 | $9.8 | $9.8 | $62.50 | $73.5K | 1.7K | 0 |
| GILD | CALL | SWEEP | BULLISH | 07/19/24 | $12.05 | $11.65 | $11.65 | $60.00 | $67.4K | 469 | 0 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | 看漲 | SWEEP | 看好 | 01/17/25 | $7.0 | $6.85 | $7.0 | 70.00美元 | $157.5K | 2.8K | 111 |
| GILD | 看漲 | SWEEP | 看淡 | 07/19/24 | 11.85美元 | $11.6 | $11.69 | $60.00 | 116.1K | 469 | 100 |
| GILD | 看跌 | SWEEP | 看好 | 09/20/24 | $3.9 | $3.75 | $3.75 | $72.50 | $96.7K | 78 | 2 |
| GILD | 看漲 | SWEEP | 看淡 | 08/16/24 | $9.85 | $9.8 | $9.8 | $62.50 | $73.5K | 1.7K | 0 |
| GILD | 看漲 | SWEEP | 看好 | 07/19/24 | $12.05 | $11.65 | $11.65 | $60.00 | $67.4K | 469 | 0 |
About Gilead Sciences
關於吉利德科學
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
吉利德科學公司開發和推廣治療威脅生命的傳染病的療法，其核心產品組合主要集中在治療艾滋病毒和乙型及丙型肝炎方面。通過收購 Corus Pharma、Myogen、CV Therapeutics、Arresto Biosciences 和 Calistoga，公司將業務口徑拓展至肺部和心血管疾病以及癌症治療領域。吉利德對 Pharmasset 的收購帶來了治療丙型肝炎藥物 Sovaldi 的權利，這也是組合藥物 Harvoni 的一部分，而 Kite、Forty Seven 和 Immunomedics 的收購則提高了吉利德在細胞治療和非細胞治療腫瘤領域中的曝光度。
Following our analysis of the options activities associated with Gilead Sciences, we pivot to a closer look at the company's own performance.
在分析與吉利德科學相關的期權交易活動之後，我們轉而更加關注公司自身的表現。
Current Position of Gilead Sciences
吉利德科學的當前位置
- Currently trading with a volume of 2,982,844, the GILD's price is up by 0.99%, now at $71.37.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 38 days.
- 目前的交易額爲 2,982,844 美元，GILD 的價格上漲了 0.99%，現在爲 71.37 美元。
- RSI讀數表明股票目前可能超買。
- 預計將在 38 天內公佈收益。
Expert Opinions on Gilead Sciences
關於吉利德科學的專家意見
In the last month, 2 experts released ratings on this stock with an average target price of $77.0.
上個月內，有 2 位專家對該股票發佈了評級，平均目標價爲 77.0 美元。
- Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Gilead Sciences, targeting a price of $80.
- An analyst from RBC Capital has revised its rating downward to Sector Perform, adjusting the price target to $74.
- 維持他們的立場，來自 Baird 的分析師繼續持有吉利德科學的中立評級，目標價爲 80 美元。
- RBC Capital 的分析師將其評級下調爲板塊表現，調整價格目標至 74 美元。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。